Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT0511 in Participants With KRAS Mutated OR Amplified Advanced Solid Tumors
NCT07300150Phase 1Recruiting
- Sponsor
- PAQ Therapeutics
- Start
- Nov 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of PT0511 in solid tumor, colorectal cancer (CRC), pancreatic cancer (PC) and 1 more (9 arms), sponsored by PAQ Therapeutics. Primary endpoints: Dose-limiting Toxicities at 21 days, Treatment-Emergent Adverse Events at 24 months and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
PT0511
03
Conditions
solid tumorcolorectal cancer (CRC)pancreatic cancer (PC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07300150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07300150.